Hypothesis

Adaptive, clock-guided dosing of OSK factors—where induction stops when a tissue‑specific methylation clock reaches a youthful threshold—achieves equal or greater rejuvenation than fixed‑duration regimens while reducing total OSK exposure and minimizing off‑target effects.

Mechanistic Rationale

Partial reprogramming with OSK resets DNA methylation at regulatory CpGs linked to aging, but the kinetics of demethylation vary across tissues because OSK‑bound enhancers differ in baseline chromatin accessibility. Tissues with open OSK‑responsive enhancers (e.g., retina, liver) recruit TET enzymes rapidly, leading to fast methylation loss; closed chromatin (e.g., pancreas, cardiomyocytes) slows this process, requiring longer exposure for comparable demethylation. Real‑time methylation clocks measure the downstream consequence of enhancer accessibility and TET activity. By tying OSK cessation to clock readout, the protocol inherently accounts for these chromatin differences, delivering the minimal effective dose for each tissue.

Experimental Design

1. Vector system – Use a dual‑AAV, doxycycline‑inducible OSK construct with a fluorescent reporter for induction verification.
2. Clock selection – Employ a multi‑tissue methylation clock comprising CpGs that show rapid demethylation in OSK‑treated retina and liver (validated in [1][5]).
3. Adaptive regimen – In mouse models of retinal injury and liver fibrosis, administer doxycycline and continuously monitor blood‑derived methylomes (or tissue biopsies at set intervals). Induction terminates when the clock‑predicted biological age falls below the non‑senescent baseline (as demonstrated in [1]).
4. Control groups – Fixed‑duration OSK (4 days, 1 week, 2 weeks) and vehicle.
5. Readouts – After 4 weeks, assess: (a) methylation age of target tissues, (b) functional recovery (electroretinogram for retina, albumin clearance for liver), (c) off‑target markers (proliferation‑associated Ki‑67, ectopic pluripotency genes), and (d) total OSK exposure (doxycycline‑days).

Expected Outcomes

• Adaptive dosing will achieve methylation age reversal comparable to the longest fixed regimen but with ~30‑40 % fewer doxycycline‑days.
• Functional improvement will be non‑inferior or superior to fixed regimens, especially in slower‑responding tissues where fixed short courses fail.
• Off‑target signals will be significantly lower in adaptive groups due to reduced cumulative OSK exposure.

Falsifiability

If adaptive OSK dosing does not reduce total exposure while matching or exceeding the methylation and functional outcomes of the best fixed‑duration protocol, the hypothesis is falsified. Similarly, if clock readout fails to predict tissue‑specific demethylation kinetics (i.e., termination occurs before youthful methylation is reached in responsive tissues or after excessive exposure in resistant tissues), the mechanistic link between enhancer accessibility and clock‑guided dosing is unsupported.